|
1
|
Yang JP, Liu Y, Zhong W, Yu D, Wen LJ and
Jin CS: Chemoresistance of CD133+ cancer stem cells in
laryngeal carcinoma. Chin Med J (Engl). 124:1055–1060.
2011.PubMed/NCBI
|
|
2
|
Chen H, Zhou L, Dou T, Wan G, Tang H and
Tian J: BMI1’S maintenance of the proliferative capacity of
laryngeal cancer stem cells. Head Neck. 33:1115–1125. 2011.
|
|
3
|
Wei XD, Zhou L, Cheng L, Tian J, Jiang JJ
and Maccallum J: In vivo investigation of CD133 as a putative
marker of cancer stem cells in Hep-2 cell line. Head Neck.
31:94–101. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhou L, Wei X, Cheng L, Tian J and Jiang
JJ: CD133, one of the markers of cancer stem cells in Hep-2 cell
line. Laryngoscope. 117:455–460. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Piao LS, Hur W, Kim TK, et al:
CD133+ liver cancer stem cells modulate radioresistance
in human hepatocellular carcinoma. Cancer Lett. 315:129–137.
2012.
|
|
6
|
Ke CC, Liu RS, Yang AH, et al:
CD133-expressing thyroid cancer cells are undifferentiated,
radioresistant and survive radioiodide therapy. Eur J Nucl Med Mol
Imaging. 40:61–71. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bao S, Wu Q, McLendon RE, et al: Glioma
stem cells promote radioresistance by preferential activation of
the DNA damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu YP, Yang CJ, Huang MS, et al:
Cisplatin selects for multidrug-resistant CD133+ cells
in lung adenocarcinoma by activating Notch signaling. Cancer Res.
73:406–416. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Neth P, Ries C, Karow M, Egea V, Ilmer M
and Jochum M: The Wnt signal transduction pathway in stem cells and
cancer cells: influence on cellular invasion. Stem Cell Rev.
3:18–29. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang D, Gao Q, Guo L, et al: Isolation
and identification of cancer stem-like cells in esophageal
carcinoma cell lines. Stem Cells Dev. 18:465–473. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gangopadhyay S, Nandy A, Hor P and
Mukhopadhyay A: Breast cancer stem cells: a novel therapeutic
target. Clin Breast Cancer. 13:7–15. 2013. View Article : Google Scholar
|
|
12
|
Ping YF, Yao XH, Jiang JY, et al: The
chemokine CXCL12 and its receptor CXCR4 promote glioma stem
cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT
signalling. J Pathol. 224:344–354. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bensinger SJ and Christofk HR: New aspects
of the Warburg effect in cancer cell biology. Semin Cell Dev Biol.
23:352–361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao K, Luo XM, Zhou SH, et al:
18F-fluorodeoxyglucose positron emission
tomography/computed tomography as an effective diagnostic workup in
cervical metastasis of carcinoma from an unknown primary tumor.
Cancer Biother Radiopharm. 27:685–693. 2012. View Article : Google Scholar
|
|
15
|
Hammoudi N, Ahmed KB, Garcia-Prieto C and
Huang P: Metabolic alterations in cancer cells and therapeutic
implications. Chin J Cancer. 30:508–525. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Varum S, Rodrigues AS, Moura MB, et al:
Energy metabolism in human pluripotent stem cells and their
differentiated counterparts. PLoS One. 6:e209142011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Han MW, Lee HJ, Cho KJ, et al: Role of
FDG-PET as a biological marker for predicting the hypoxic status of
tongue cancer. Head Neck. 34:1395–1402. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li XF, Ma Y, Sun X, Humm JL, Ling CC and
O’Donoghue JA: High 18F-FDG uptake in microscopic peritoneal tumors
requires physiologic hypoxia. J Nucl Med. 51:632–638. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Alakus H, Batur M, Schmidt M, et al:
Variable 18F-fluorodeoxyglucose uptake in gastric cancer is
associated with different levels of GLUT-1 expression. Nucl Med
Commun. 31:532–538. 2010.PubMed/NCBI
|
|
20
|
Nagamatsu A, Umesaki N, Li L and Tanaka T:
Use of 18F-fluorodeoxyglucose positron emission tomography for
diagnosis of uterine sarcomas. Oncol Rep. 23:1069–1076.
2010.PubMed/NCBI
|
|
21
|
Zhou S, Wang S, Wu Q, Fan J and Wang Q:
Expression of glucose transporter-1 and -3 in the head and neck
carcinoma--the correlation of the expression with the biological
behaviors. ORL J Otorhinolaryngol Relat Spec. 70:189–194. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li LF, Zhou SH, Zhao K, et al: Clinical
significance of FDG single-photon emission computed tomography:
Computed tomography in the diagnosis of head and neck cancers and
study of its mechanism. Cancer Biother Radiopharm. 23:701–714.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mai HM, Zheng JW, Wang YA, et al: CD133
selected stem cells from proliferating infantile hemangioma and
establishment of an in vivo mice model of hemangioma. Chin Med J
(Engl). 126:88–94. 2013.PubMed/NCBI
|
|
24
|
Loda M, Xu X, Pession A, Vortmeyer A and
Giangaspero F: Membranous expression of glucose transporter-1
protein (GLUT-1) in embryonal neoplasms of the central nervous
system. Neuropathol Appl Neurobiol. 26:91–97. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu XH, Chen SP, Mao JY, Ji XX, Yao HT and
Zhou SH: Expression and significance of hypoxia-inducible factor-1α
and glucose transporter-1 in laryngeal carcinoma. Oncol Lett.
5:261–266. 2013.
|
|
26
|
Xu YY, Bao YY, Zhou SH and Fan J: Effect
on the expression of MMP-2, MT-MMP in laryngeal carcinoma Hep-2
cell line by antisense glucose transporter-1. Arch Med Res.
43:395–401. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou SH, Fan J, Chen XM, Cheng KJ and Wang
SQ: Inhibition of cell proliferation and glucose uptake in human
laryngeal carcinoma cells by antisense oligonucleotides against
glucose transporter-1. Head Neck. 31:1624–1633. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Korkeila E, Jaakkola PM, Syrjänen K,
Pyrhönen S and Sundström J: Pronounced tumour regression after
radiotherapy is associated with negative/weak glucose transporter-1
expression in rectal cancer. Anticancer Res. 31:311–315.
2011.PubMed/NCBI
|
|
29
|
Chiba I, Ogawa K, Morioka T, et al:
Clinical significance of GLUT-1 expression in patients with
esophageal cancer treated with concurrent chemoradiotherapy. Oncol
Lett. 2:21–28. 2011.PubMed/NCBI
|
|
30
|
Kunkel M, Moergel M, Stockinger M, et al:
Overexpression of GLUT-1 is associated with resistance to
radiotherapy and adverse prognosis in squamous cell carcinoma of
the oral cavity. Oral Oncol. 43:796–803. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Eckert AW, Kappler M, Schubert J and
Taubert H: Correlation of expression of hypoxia-related proteins
with prognosis in oral squamous cell carcinoma patients. Oral
Maxillofac Surg. 16:189–196. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rademakers SE, Lok J, van der Kogel AJ,
Bussink J and Kaanders JH: Metabolic markers in relation to
hypoxia; staining patterns and colocalization of pimonidazole,
HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer.
11:1672011.PubMed/NCBI
|
|
33
|
Cao X, Fang L, Gibbs S, et al: Glucose
uptake inhibitor sensitizes cancer cells to daunorubicin and
overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol.
59:495–505. 2007. View Article : Google Scholar : PubMed/NCBI
|
